Skip to main content

Table 3 Medication adherence for the UMEC/VI and TIO cohorts

From: Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study

 

UMEC/VI (N = 3929)

TIO (N = 3929)

p valuea

Difference (95% CI)

Odds ratio (95% CI)

PDC, mean (SD) [median]

0.44 (0.32) [0.33]

0.37 (0.31) [0.25]

 < 0.001

0.06 (0.05, 0.08)

–

Proportion with PDC ≥ 0.8, n (%)

863 (22.0)

646 (16.4)

 < 0.001

–

1.44 (1.28, 1.61)

  1. ap-values were calculated using paired t-tests for mean PDC and McNemar tests for proportion of patients with PDC ≥ 0.8
  2. CI, confidence interval; PDC, proportion of days covered; SD, standard deviation; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us